期刊
BMC HEALTH SERVICES RESEARCH
卷 14, 期 -, 页码 -出版社
BMC
DOI: 10.1186/1472-6963-14-201
关键词
Antiretroviral therapy; Pediatric HIV; Costs
资金
- National Institutes of Health, including the National Institute of Allergy and Infectious Disease (NIAID) [K01 AI078754, R01 AI058736]
- IMPAACT network (NIAID)
- IMPAACT network (Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD))
- Johns Hopkins University [UM AI068632]
- World Health Organization
- National Institute of Allergy and Infectious Diseases (NIAID) [U01 AI068632]
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- National Institute of Mental Health (NIMH) [AI068632]
- Statistical and Data Analysis Center at Harvard School of Public Health
- ational Institute of Allergy and Infectious Diseases cooperative agreement [5 U01 AI41110]
- Pediatric AIDS Clinical Trials Group (PACTG) [1 U01 AI068616]
- National Institute of Allergy and Infectious Diseases (NIAID)
- NICHD International and Domestic Pediatric and Maternal HIV Clinical Trials Network funded by NICHD [N01-DK-9-001/HHSN267200800001C]
Background: Pediatric antiretroviral therapy (ART) has been shown to substantially reduce morbidity and mortality in HIV-infected infants and children. To accurately project program costs, analysts need accurate estimations of antiretroviral drug (ARV) costs for children. However, the costing of pediatric antiretroviral therapy is complicated by weight-based dosing recommendations which change as children grow. Methods: We developed a step-by-step methodology for estimating the cost of pediatric ARV regimens for children ages 0-13 years old. The costing approach incorporates weight-based dosing recommendations to provide estimated ARV doses throughout childhood development. Published unit drug costs are then used to calculate average monthly drug costs. We compared our derived monthly ARV costs to published estimates to assess the accuracy of our methodology. Results: The estimates of monthly ARV costs are provided for six commonly used first-line pediatric ARV regimens, considering three possible care scenarios. The costs derived in our analysis for children were fairly comparable to or slightly higher than available published ARV drug or regimen estimates. Conclusions: The methodology described here can be used to provide an accurate estimation of pediatric ARV regimen costs for cost-effectiveness analysts to project the optimum packages of care for HIV-infected children, as well as for program administrators and budget analysts who wish to assess the feasibility of increasing pediatric ART availability in constrained budget environments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据